SightGlass Vision Clinical Trial to Control Childhood Nearsightedness Is Now Enrolling Patients

By

PALO ALTO, Calif.—SightGlass Vision, Inc. has announced that CYPRESS, a clinical trial to control nearsightedness in children, is now enrolling patients in the U.S. and Canada. This CYPRESS study will evaluate the safety and efficacy of SightGlass Vision’s novel lenses compared to standard lenses to reduce the rate of progression of myopia in children between the ages of six and nine over the course of 36 months. The multicenter, double-blinded, randomized controlled trial will enroll 255 patients across 14 sites in the U.S. and Canada. SightGlass expects to complete trial enrollment by the end of Q1 2019, and to report their initial results in 2020, which will later be accompanied by additional data after a longer-term follow up.


Trial participants can choose from a variety of styles for their eyeglasses, which will be provided at no cost. Families will also be compensated for travel and other expenses, and participating children will receive free comprehensive eyecare throughout the duration of the study.

"Although some people view myopia as an ordinary, often unavoidable condition, it has been well established that it often progresses rapidly during childhood. This results in the need for stronger prescription glasses and increases the risk of potentially blinding conditions such as glaucoma and retinal detachment in adulthood," said Katie Gilbert-Spear, OD, MPH, principal investigator in Pensacola, Florida. "We are pleased to be part of the CYPRESS program to study SightGlass's novel lenses which could help revolutionize myopia care."

Interested parents can visit www.kidsvision.info to learn more.